Ubs Group Ag Axcella Health Inc. Call Options Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding AXLA

# of Institutions
2
Shares Held
61.6K
Call Options Held
0
Put Options Held
0
View Full List

About Axcella Health Inc.

AXLA Quotes by TradingView
  • Ticker AXLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,500,896
  • Description
  • Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrenc...
More about AXLA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email